New research may lead to new therapy for baldness

Until 2012, the male pattern baldness thought to be caused by AGA (androgenetic or androgenic alopecia). It believes that hair loss is caused by underlying susceptibility of hair follicles to androgen miniaturization. The condition affects more than 70 percent men and 40 percent of women at some point of life. Classic example of the condition is men developing it starting at the temples and vertex. In females, it causes thinning of hair without hairline recession. Both male and female pattern baldness do not cause total hair loss.

In 2012, the researchers at the University of Pennsylvania found a gene known as Prostaglandin D₂ (PGD₂) is abnormally high in bald scalps. The research paper indicates a link between elevated levels of localized prostaglandin D₂ and hair growth inhabitation. The levels were much higher with persons who were balding. De-activation of PGD₂ will allow hair follicle growth to continue. Fortunately, PGD₂ has also been linked to asthma and nasal condition known as allergic rhinitis for several years, treatments for PGD₂ were already in development. They will have to complete trials and get approval from the Food and Drug Administration. Hopefully, there will be a new therapy available soon for baldness.